Thermo Fisher Scientific Inc. EV/EBITDA
Data as of June 01, 2026
EV/EBITDA
19.75
Enterprise Value
$223.06B
EBITDA (TTM)
$11.30B
Sector
Healthcare
How It's Calculated
19.75 = $223.06B ÷ $11.30B
What This Means
Thermo Fisher Scientific Inc.'s EV/EBITDA of 19.7 is in a moderate range for Healthcare.
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. (TMO) operates in the Healthcare sector, specifically in Diagnostics & Research. With a market capitalization of about $183.03B, it ranks as a large-cap stock — a major established company.
Shares recently traded near $492.51, within a 52-week range of $385.46 to $643.99 (-23.5% from the high, +27.8% from the low). Beta of 0.88 is broadly in line with typical market sensitivity.
Trailing profit margin is about 15.2%, signaling a solid profit margin for its industry.
Understanding This Metric
EV/EBITDA is widely used when comparing companies with different debt loads because enterprise value includes net debt while EBITDA approximates operating cash earnings power. For Thermo Fisher Scientific Inc., the ratio should be read with growth, capex needs, and cycle position in Healthcare. Pair EV/EBITDA with free cash flow yield and net debt metrics before drawing conclusions — especially when EBITDA is depressed or boosted by one-time items.
Using This Number in Practice
Near 19.75x EV/EBITDA, Thermo Fisher Scientific Inc. (TMO) carries an elevated EV/EBITDA multiple that may embed growth expectations or scarcity within its peer set. Enterprise value of about $223.06B and EBITDA near $11.30B form the ratio — adjust for one-time items before treating the headline multiple as comparable.
Credit and LBO workflows often sort names on EV/EBITDA before drilling into free cash flow and maintenance capex. Pair this view with the EV/EBITDA calculator and the TMO metrics hub for related valuation pages.
Sector Comparison
Among Healthcare names on our S&P 100 coverage, Thermo Fisher Scientific Inc.'s EV/EBITDA of 19.75 can be compared with peers such as LLY (28.26), JNJ (16.76), UNH (18.61). Sector context helps interpretation, but each company's growth profile and balance sheet differ — use multiple metrics before drawing conclusions. View all Healthcare stocks.
Key Takeaways
- TMO is grouped in the Healthcare sector for peer comparisons.
- Recent beta of 0.88 suggests lower-than-market price sensitivity.
- Trailing profit margin of 15.2% provides context for how much earnings support the headline multiple.
Related Tools & Guides
Explore calculators and guides connected to this metric, or view all metrics for TMO.
Other TMO Metrics
Frequently Asked Questions
What is TMO's EV/EBITDA?
EV/EBITDA compares enterprise value to operating earnings before interest, taxes, depreciation, and amortization. Thermo Fisher Scientific Inc.'s ratio is about 19.75 — common for comparing leveraged companies in Healthcare.
Is 19.75 high or low vs peers?
Among Healthcare peers (e.g. LLY (28.26), UNH (18.61), DHR (18.06)), TMO's 19.75 should be read with growth, capex, and debt levels.
When is EV/EBITDA misleading?
EBITDA ignores capex, working capital, and stock-based comp; negative or tiny EBITDA makes the ratio meaningless. Cross-check with free cash flow and net debt.
Calculate the ev/ebitda for any stock with our free calculator.
Open EV/EBITDA Calculator →